| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f9752d848f5824cbabb8a5c6c8178a5e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7e5f28477bdfb0f7e85110403e40ac85 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-523
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5258
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5254
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2770-32151
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2770-32123
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2770-32122
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2770-32134 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-005
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N7-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Y304-22044
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-506
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-96 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N7-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N9-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N9-96
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-005 |
| filingDate |
2019-03-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c73051c9d8ce4935d648e37a4ab05bc6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9d0af6d83b2739646c16d5ea628f2fc5 |
| publicationDate |
2019-07-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2019211321-A1 |
| titleOfInvention |
Processing engineered fmdv p1 polypeptide using an alternative tev protease |
| abstract |
Polynucleotide constructs that express an engineered foot-and-mouth disease (FMDV) P1 precursor protein and a non-FMDV TEV protease and methods for safe and efficient recombinant production of FMDV antigens and immunogens. Recombinant production of FMDV antigens avoids the need to culture highly-infectious FMDV, while conventional culture methods for producing FMDV antigens rely on the native FMDV 3C protease which exerts toxic effects on host cells. The inventors have developed a new system that efficiently and safely processes FMDV P1 precursor without the FMDV 3C protease, thus avoiding the toxic effects associated with use of the 3C protease. The invention is also directed to the FMDV antigens and virus-like particles produced by this system as well as to FMDV vaccines, diagnostics and other biologics. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-102513632-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022093741-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11008564-B2 |
| priorityDate |
2017-01-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |